Stockscreener 앱 받기
3.10
25.41%
0.64
Phio Pharmaceuticals Corp 주식(PHIO)의 최신 뉴스
Phio Pharmaceuticals appoints new strategic and finance VPs - Investing.com India
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - TradingView
Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan
Phio Pharmaceuticals (NASDAQ:PHIO) Now Covered by HC Wainwright - Defense World
Phio Pharma (PHIO) Receives Buy Rating and $14 Price Target from HC Wainwright | PHIO Stock News - GuruFocus
H.C. Wainwright assumes coverage on Phio Pharma stock with Buy rating - Investing.com
Phio Pharmaceuticals (PHIO) Gains 'Buy' Rating with Promising Price Target | PHIO Stock News - GuruFocus
Why BioNTech Stock Soared Today - The Globe and Mail
Best Value Stocks to Buy for May 28th - The Globe and Mail
New Strong Buy Stocks for May 28th - The Globe and Mail
New Strong Buy Stocks For May 28th - Barchart.com
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - The Globe and Mail
Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile
Phio Reveals Latest Progress on Revolutionary Cancer-Fighting siRNA Technology at Investor Conference - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile
Why JD.com Stock Slumped on Thursday - The Globe and Mail
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks
Phio reports positive results in skin cancer trial - Investing.com
Phio reports positive results in skin cancer trial By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals (PHIO) to Release Earnings on Thursday - Defense World
Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts
Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister
Best Momentum Stocks to Buy for April 23rd - TradingView
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com
Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World
Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN
3 Penny Stocks to Watch Now, 4/10/25 - TipRanks
Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled - MSN
Phio advances skin cancer treatment with successful trial By Investing.com - Investing.com South Africa
This Biotech Is Ripping Following Phase 1b Trial Announcement - The Globe and Mail
Crude Oil Down 4%; Neogen Shares Plunge After Q3 ResultsBloom Energy (NYSE:BE), Neogen (NASDAQ:NEOG) - Benzinga
Phio Pharmaceuticals Advances PH-762 Cancer Treatment in Phase 1 - GuruFocus
PHIO Advances PH-762 in Phase 1b Clinical Trial for Skin Cancers - GuruFocus
Is Phio’s Surge Sustainable? - timothysykes.com
Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation - marketscreener.com
Phio advances skin cancer treatment with successful trial - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile
1.30%
3.35%
자본화:
|
볼륨(24시간):